跳至主要内容
临床试验/NCT06681233
NCT06681233招募中不适用

A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients

Varian, a Siemens Healthineers Company4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年2月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50
试验地点
4
主要终点
Comparison of Image Contrast Resolution

研究概览

简要总结

Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.

Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.

This study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.

The goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient age ≥ 18
  • Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies
  • A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered

排除标准

  • Patient has ECOG Performance Status ≥
  • Patient is wheelchair bound.
  • Patient has a life expectancy <3 months.
  • Patient is unwilling or unable to provide informed consent to participate in the study.
  • Patient is pregnant or has plans for pregnancy during the period of treatment.
  • Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.

研究组 & 干预措施

HyperSight Imaging Arm

Experimental

干预措施: Comparison of HyperSight CBCT imaging to conventional CBCT imaging. (Device)

结局指标

主要结局

Comparison of Image Contrast Resolution

时间窗: End of radiation treatment at 9 weeks.

The difference in contrast resolution will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process

Comparison of Image Uniformity

时间窗: End of radiation treatment at 9 weeks.

The difference in image uniformity will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process.

Qualitative Image Comparison

时间窗: End of radiation treatment at 9 weeks.

Qualitative comparison of HyperSight CBCT to conventional CBCT to determine preferred imaging for patient localization for daily treatment. Clinician observers will rank their preference using a 5-point Likert scale, where 1 represents strong preference of one imaging modality and 5 represents strong preference for the other modality.

次要结局

  • Reduction of Metal Artifacts(End of radiation treatment at 9 weeks.)
  • Imaging Time for Large Treatment Volumes(End of radiation treatment at 9 weeks.)
  • Imaging Time for Breath Hold Imaging(End of radiation treatment at 9 weeks.)
  • Patient Tolerance of Breath Hold Imaging(End of radiation treatment at 9 weeks.)
  • Feasibility of HyperSight CBCT for Treatment Planning(End of radiation treatment at 9 weeks.)

研究者

发起方
Varian, a Siemens Healthineers Company
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验